Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy

ABSTRACT Background Prior studies in patients with BRAF‐mutant melanoma have shown increased density of tumor infiltrating lymphocytes (TIL) after 2 weeks of BRAF (BRAFi) ± MEK inhibition (MEKi), but did not characterize the functional state or clonal diversity of TIL over time. We evaluated sequent...

Полное описание

Библиографические подробности

Главные авторы:	Suthee Rapisuwon, Craig L. Slingluff Jr., Jennifer A. Wargo, Ryan J. Sullivan, Benjamin Izar, Jia‐Ren Lin, Ileana S. Mauldin, Walter C. Olson, Christine A. Tran, Gabrielle H. Schwartzman, Geoffrey T. Gibney, Waddah Al‐Refaie, Michael B. Atkins
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Wiley 2026-01-01
Серии:	Cancer Medicine
Предметы:	BRAF/MEK inhibitor therapy melanoma tumor immune microenvironment
Online-ссылка:	https://doi.org/10.1002/cam4.71526
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!